MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Establishment Labs Holdings Gross Profit 2011-2026 | ESTA
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Establishment Labs Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 146 M | 110 M | 107 M | 107 M | 85.4 M | 52.5 M | 54.9 M | 36.1 M | 17.7 M | 10.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 146 M | 10.1 M | 72.6 M |
Quarterly Gross Profit Establishment Labs Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.7 M | 35.3 M | 27.8 M | - | 25.7 M | 28.9 M | 24.4 M | - | 26.1 M | 30.3 M | 30.1 M | - | 26 M | 27.5 M | 24.9 M | - | 19.6 M | 21.5 M | 20.1 M | - | 15.1 M | 7.23 M | 15.5 M | - | 14.2 M | 13 M | 11.3 M | - | 10.1 M | 8.22 M | 7.92 M | - | 3.6 M | 4.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 37.7 M | 3.6 M | 19.9 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Butterfly Network
BFLY
|
48.8 M | $ 4.19 | 5.67 % | $ 887 M |  USA |
 |
InMode Ltd.
INMD
|
291 M | $ 13.73 | 1.48 % | $ 887 M |  Israel |
 |
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
1.65 B | $ 34.86 | 4.68 % | $ 5.19 K | USA |
 |
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
22.7 M | $ 9.51 | 5.32 % | $ 269 M | USA |
 |
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | USA |
 |
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
532 M | $ 12.15 | -1.78 % | $ 1.82 B | USA |
 |
Delcath Systems
DCTH
|
73.4 M | $ 9.1 | 0.33 % | $ 326 M | USA |
 |
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | USA |
 |
AxoGen
AXGN
|
167 M | $ 31.75 | 3.15 % | $ 1.46 B | USA |
 |
CONMED Corporation
CNMD
|
750 M | $ 36.63 | 1.92 % | $ 1.14 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 82.02 | -0.58 % | $ 48 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Electromed
ELMD
|
50 M | $ 24.49 | 5.2 % | $ 207 M | USA |
 |
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.67 | 2.06 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
1.36 M | $ 2.3 | 6.48 % | $ 3.59 M | USA |
 |
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | USA |
 |
Helius Medical Technologies
HSDT
|
61 K | $ 2.06 | 0.98 % | $ 1.25 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 9.43 | 5.48 % | $ 726 M | USA |
 |
AdaptHealth Corp.
AHCO
|
89.3 M | $ 10.37 | 4.64 % | $ 1.4 B | USA |
 |
IRIDEX Corporation
IRIX
|
21.8 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
64.3 M | $ 99.2 | -0.3 % | $ 1.26 B | USA |
 |
FONAR Corporation
FONR
|
42.4 M | $ 18.34 | -0.22 % | $ 120 M | USA |
 |
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
26.6 M | $ 3.73 | 3.32 % | $ 139 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
173 M | $ 16.47 | -0.3 % | $ 386 M | USA |
 |
Inspire Medical Systems
INSP
|
779 M | $ 52.16 | -2.9 % | $ 1.53 B | USA |
 |
LivaNova PLC
LIVN
|
940 M | $ 63.24 | 1.69 % | $ 3.45 B |  Britain |
 |
Medtronic PLC
MDT
|
19.6 B | $ 87.17 | 1.13 % | $ 112 B | USA |
 |
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.39 | 2.21 % | $ 56.6 M | USA |
 |
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | USA |
 |
Myomo
MYO
|
26.9 M | $ 0.71 | 0.08 % | $ 29.7 M | USA |
 |
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | USA |